Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine
SEATTLE, WA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the presentation of preclinical data from two independent studies at the World Molecular Imaging Congress (WMIC) 2023, held on September 5-9, 2023, in Prague, Czech Republic, and the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria, from September 9-13, 2023.
- Dr. Michael K. Schultz, Chief Scientific Officer at Perspective Therapeutics, presented research at the WWIC on the potential of lead-based targeted alpha particle therapy using [212Pb]VMT-α-NET for the treatment of neuroendocrine tumors (NETs).
- The study was carried out by Dr. Dongyoul Lee, an assistant professor at the Korea Military Academy.
- The dose depositions in tumor and normal organs were estimated based on 203Pb biodistribution data.
- In addition, tumor progression, survival rates, and body weight changes over a 120-day period were assessed, and favorable radiochemical characteristics were observed.